Merck & Co., Inc. is set to announce its latest quarterly earnings on Wednesday, April 29th, with a consensus estimate of -$1.47 EPS.
Today, Merck & Co., Inc. (MRK) is trading at $111.63, up $1.4 (1.27%) from the previous close of $110.23. The trading volume is $1.59 million, representing a 14.26% increase compared to the average.
In the most recent earnings report released on Monday, February 2nd, Merck & Co., Inc. surpassed expectations with an EPS of $2.04.
Merck & Co., Inc. offers a forward dividend yield of 3.05%. The company distributed 85 cents per share MRQ, showing a year-over-year growth of 5.13 cents.
The company's cash flow indicates a net change of -$3.51 billion, with operating cash flow at $2.86 billion and debt repayment of -$7.85 billion.
Merck & Co., Inc. reported a revenue of $16.4 billion, gross profit of $15.2 billion, and a net income of $2.96 billion. The EPS stands at $1.19.
Key ratios for Merck & Co., Inc. include a gross profit margin of 92.71%, net profit margin of 18.07%, and return on equity of 5.63%.
The balance sheet shows total assets of $136.87 billion, total liabilities of $84.20 billion, and net debt of $35.97 billion for Merck & Co., Inc.
This comprehensive analysis provides insights into Merck & Co., Inc.'s financial performance and expectations, giving investors a clearer picture of the company's current standing.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.